RAVE
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Patient / Population Intervention / Exposure Comparison Outcome
In 197 patients with severe ANCA-associated vasculitis, rituximab was non-inferior for inducing remission compared with cyclophosphamide.
N
197
Design
Double-blind, double-dummy RCT
Endpoint
Complete remission without steroids at month 6
Relevance
1
ResultRituximab 64% vs cyclophosphamide 53% (non-inferior); superior in the relapsing subgroup.
Stone JH, et al. N Engl J Med. 2010;363(3):221-232. 10.1056/NEJMoa0909905
Discussion & critique
Established rituximab as standard induction in ANCA vasculitis, sparing cyclophosphamide exposure.